Financhill
Sell
6

NVEE Quote, Financials, Valuation and Earnings

Last price:
$15.53
Seasonality move :
12.83%
Day range:
$15.18 - $17.42
52-week range:
$15.18 - $26.14
Dividend yield:
0%
P/E ratio:
31.31x
P/S ratio:
1.02x
P/B ratio:
1.21x
Volume:
774.3K
Avg. volume:
619.9K
1-year change:
-35.44%
Market cap:
$1B
Revenue:
$941.3M
EPS (TTM):
$0.49

Earnings Data

Next earnings date for NVEE
May 08
2025
Most recent earnings per share
$0.09
Missed by $0.19
(Feb 20/2025)
Consensus Estimate
$0.28
(Feb 20/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

NVEE Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
06/30/2025 Q2 $251.7M -- -- $0.32 --
05/08/2025 Q1 $229.9M -- -- $0.19 --
02/20/2025 Q4 $242.2M $246.5M $0.09 $0.28 -$0.19
11/07/2024 Q3 $251.4M $250.9M $0.27 $0.40 -$0.13
08/07/2024 Q2 $235M $236.3M $0.13 $0.30 -$0.17
05/08/2024 Q1 $209.2M $213.3M $0.01 $0.19 -$0.18
02/22/2024 Q4 $217.7M $219.4M $0.16 $0.30 -$0.14
11/02/2023 Q3 $238M $237.5M $0.21 $0.36 -$0.15
08/09/2023 Q2 $222.2M $222.6M $0.25 $0.31 -$0.06
05/04/2023 Q1 $188.3M $184.3M $0.10 $0.21 -$0.11
02/23/2023 Q4 $203.3M $189.8M $0.13 $0.39 -$0.26
11/03/2022 Q3 -- $204.1M $0.26 -- --
08/04/2022 Q2 -- $202.7M $0.28 -- --
05/05/2022 Q1 -- $190.2M $0.14 -- --
02/28/2022 Q4 -- $188.6M $0.26 -- --
11/09/2021 Q3 -- $185.6M $0.21 -- --
08/10/2021 Q2 -- $179.5M $0.23 -- --
05/12/2021 Q1 -- $153.1M $0.10 -- --
03/02/2021 Q4 -- $161.2M $0.09 -- --
11/11/2020 Q3 -- $169.9M $0.15 -- --
08/05/2020 Q2 -- $162.7M $0.09 -- --
05/07/2020 Q1 -- $165.5M $0.08 -- --
02/26/2020 Q4 -- $132.6M $0.07 -- --
11/07/2019 Q3 -- $131M $0.12 -- --
08/07/2019 Q2 -- $128M $0.18 -- --
05/08/2019 Q1 -- $117.3M $0.11 -- --
03/07/2019 Q4 -- $115.3M $0.16 -- --
11/07/2018 Q3 -- $104.2M $0.16 -- --
08/02/2018 Q2 -- $104M $0.17 -- --
05/03/2018 Q1 -- $94.5M $0.10 -- --
03/08/2018 Q4 -- $94M $0.27 -- --
11/08/2017 Q3 -- $91.3M $0.14 -- --
08/03/2017 Q2 -- $83.7M $0.10 -- --
05/04/2017 Q1 -- $64.1M $0.05 -- --
03/09/2017 Q4 -- $63M $0.08 -- --
11/03/2016 Q3 -- $60.1M $0.08 -- --
08/05/2016 Q2 -- $55.9M $0.08 -- --
05/05/2016 Q1 -- $44.9M $0.06 -- --
03/10/2016 Q4 -- $42.3M $0.08 -- --
11/12/2015 Q3 -- $48.7M $0.10 -- --
08/13/2015 Q2 -- $34.5M $0.06 -- --

NV5 Global Earnings Questions

  • How Much did NV5 Global Generate in Revenue Last Quarter?

    NV5 Global reported $246.5M worth of top line sales in its most recent quarter.

  • Did NV5 Global Beat Earnings Last Quarter?

    NV5 Global announced earnings per share of $0.09 which represents a miss of analyst forecast a $0.28 per share.

  • Is NV5 Global Profitable?

    NV5 Global reported $122.2M that represents $1.93 per share over the last quarter.

  • What is the Analyst Consensus for NV5 Global EPS Next Year?

    NV5 Global's earnings are forecast to grow from $0.44 per share to $1.19 per share next year representing an increase of 194.81%.

  • When is NV5 Global's Earnings Date?

    NV5 Global's next earnings date is May 8, 2025.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Down 50%, Is Dell Technologies a Buy?
Down 50%, Is Dell Technologies a Buy?

Dell (NYSE:DELL)’s share price has been on a roller coaster…

How Bad Will the Stock Market Get?
How Bad Will the Stock Market Get?

In recent trading days, global stock markets have seen massive…

Is JOBY Stock a Buy, Sell or Hold?
Is JOBY Stock a Buy, Sell or Hold?

Joby Aviation (NYSE:JOBY) got started with the big idea of…

Stock Ideas

Sell
36
Is MSFT Stock a Buy?

Market Cap: $2.6T
P/E Ratio: 30x

Sell
30
Is AAPL Stock a Buy?

Market Cap: $2.6T
P/E Ratio: 28x

Sell
33
Is NVDA Stock a Buy?

Market Cap: $2.3T
P/E Ratio: 33x

Alerts

Buy
55
SLNO alert for Apr 9

Soleno Therapeutics [SLNO] is up 6.76% over the past day.

Sell
20
HELE alert for Apr 9

Helen Of Troy [HELE] is up 4.97% over the past day.

Sell
18
OXM alert for Apr 9

Oxford Industries [OXM] is up 12.27% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock